Loss of E-cadherin and upregulation of ALDH1 and EMT markers in breast cancer stem cells may play a role in tumorigenesis or metastatasis (Papadaki et al., 2014), which could have negative impacts on overall and progression-free survival in clinical trials using SIRPα-based therapeutics to treat triple negative breast cancer. This evidence concerns the gene SIRPA and triple-negative breast carcinoma.